The phase I ACE-Gastric-01 trial explored the tolerability and antitumor activity of ARX788 in patients with previously treated HER2-positive advanced G/GEJ adenocarcinoma [80]. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.